Endonovo Therapeutics, Inc. - ENDV stock
OTC Symbol: ENDV | OTC Tier: Pink Current
About Endovo[edit]
Endonovo Therapeutics Inc. (OTC: ENDV) is a publicly-traded biotechnology company headquartered in Woodland Hills, California. The company specializes in developing non-invasive bioelectronic therapies for a variety of inflammatory and autoimmune diseases. Their proprietary technology is based on the application of pulsed electromagnetic fields (PEMFs) to the body.
Products[edit]
SofPulse[edit]
Endonovo's flagship product is called SofPulse, which is an FDA-cleared, non-invasive PEMF device for the treatment of pain and edema. SofPulse uses low-intensity PEMFs to stimulate the body's natural healing processes and reduce inflammation. The device has been used successfully in a variety of clinical settings, including hospitals, rehabilitation centers, and sports medicine clinics.
Development[edit]
In addition to SofPulse, Endonovo is also developing a pipeline of other bioelectronic therapies for conditions such as traumatic brain injury, liver disease, and sepsis. The company's goal is to develop safe and effective therapies that can improve patient outcomes and reduce the need for more invasive treatments.
Partnerships[edit]
Endonovo has partnerships with a number of leading academic institutions and has received funding from the National Institutes of Health (NIH) to support its research efforts. The company is publicly traded on the OTCQB market under the ticker symbol ENDV.
